Related Experiment Video
Updated: Jun 18, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes
Yehuda Handelsman1, Stacey L Abby, Xiaoping Jin
1Metabolic Institute of America, Tarzana, CA 91356, USA. yhandelsman@pacbell.net
Abstract:
Although colesevelam hydrochloride (HCl) is indicated to reduce low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and improve glycemic control in patients with type 2 diabetes, its effects on glucose and lipids in patients with prediabetes have not been previously studied. To evaluate the effects of colesevelam HCl in patients with prediabetes, a post-hoc analysis was conducted on data from a 24-week lipid-lowering study. Using baseline laboratory safety data for fasting plasma glucose (FPG), 88 patients were identified as having prediabetes according to American Diabetes Association criteria. Fasting plasma glucose was reduced by 4.0 mg/dL with colesevelam HCl 3.8 g/day and by 6.1 mg/dL with colesevelam HCl 4.5 g/day compared with placebo. Additionally, LDL-C was reduced by 13.2% and 12.0% with colesevelam HCl 3.8 and 4.5 g/day, respectively, versus placebo. Colesevelam HCl 3.8 g/day also significantly reduced total cholesterol and apolipoprotein (apo)B levels, whereas no significant difference in high-density lipoprotein cholesterol, apoA-I, or triglyceride levels was observed versus placebo. In patients with hyperlipidemia and prediabetes, colesevelam HCl improved glycemic control and the lipid profile.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Sulfonylureas
Hyperglycemia
Dipeptidyl Peptidase 4 Inhibitors
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...